Soleus Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 429.36%
(FY 2022)
- Profit 138.17%
(FY 2022)
- Ebitda 91.19%
(FY 2022)
- Net Worth 49.52%
(FY 2022)
- Total Assets 9.54%
(FY 2022)
About Soleus Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Alivarsh Saifi, Ashish Mishra, Moseeb Khan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24304MH2019PTC328827
- Company No.
328827
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Soleus Pharmaceutical Private Limited offer?
Soleus Pharmaceutical Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs.
Who are the key members and board of directors at Soleus Pharmaceutical?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Mishra  | Director | 02-Aug-2019 | Current |
| Alivarsh Saifi | Director | 02-Aug-2019 | Current |
| Moseeb Khan | Director | 02-Aug-2019 | Current |
| Mohd Anees | Additional Director | 22-Sep-2024 | Current |
| Shabbir Zaveri | Director | 05-Aug-2021 | Current |
Financial Performance of Soleus Pharmaceutical.
Soleus Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 429.36% increase. The company also saw a substantial improvement in profitability, with a 138.17% increase in profit. The company's net worth Soared by an impressive increase of 49.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Soleus Pharmaceutical?
In 2022, Soleus Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Soleus Pharmaceutical?
Unlock and access historical data on people associated with Soleus Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Soleus Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Soleus Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
